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Abstract
Introduction and Objectives: Lymphatic metastasis is a common occurrence in human breast cancer, mechanisms
remaining poorly understood. MDA-MB-468LN (468LN), a variant of the MDA-MB-468GFP (468GFP) human breast cancer cell
line, produces extensive lymphatic metastasis in nude mice. 468LN cells differentially express a9b1 integrin, a receptor for
lymphangiogenic factors VEGF-C/-D. We explored whether (1) differential production of VEGF-C/-D by 468LN cells provides
an autocrine stimulus for cellular motility by interacting with a9b1 and a paracrine stimulus for lymphangiogenesis in vitro
as measured with capillary-like tube formation by human lymphatic endothelial cells (HMVEC-dLy); (2) differential
expression of a9 also promotes cellular motility/invasiveness by interacting with macrophage derived factors; (3) stable
knock-down of VEGF-D or a9 in 468LN cells abrogates lymphangiogenesis and lymphatic metastasis in vivo in nude mice.
Results: A comparison of expression of cyclo-oxygenase (COX)-2 (a VEGF-C/-D inducer), VEGF-C/-D and their receptors
revealed little COX-2 expression by either cells. However, 468LN cells showed differential VEGF-D and a9b1 expression,
VEGF-D secretion, proliferative, migratory/invasive capacities, latter functions being stimulated further with VEGF-D. The
requirement of a9b1 for native and VEGF-D-stimulated proliferation, migration and Erk activation was demonstrated by
treating with a9b1 blocking antibody or knock-down of a9. An autocrine role of VEGF-D in migration was shown by its
impairment by silencing VEGF-D and restoration with VEGF-D. 468LN cells and their soluble products stimulated tube
formation, migration/invasiveness of HMVEC-dLy cell in a VEGF-D dependent manner as indicated by the loss of stimulation
by silencing VEGF-D in 468LN cells. Furthermore, 468LN cells showed a9-dependent stimulation of migration/invasiveness
by macrophage products. Finally, capacity for intra-tumoral lymphangiogenesis and lymphatic metastasis in nude mice was
completely abrogated by stable knock-down of either VEGF-D or a9 in 468LN cells.
Conclusion: Differential capacity for VEGF-D production and a9b1 integrin expression by 468LN cells jointly contributed to
their lymphatic metastatic phenotype.
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Introduction
Metastasis by the lymphatic route, often the first mode of spread
of human breast cancer, negatively impacts patient survival [1].
However, the underlying mechanisms remain poorly understood.
Vascular endothelial growth factors (VEGF)-C and -D were shown
to stimulate lymphangiogenesis by binding to VEGF receptor (R)-
3 expressed by lymphatic endothelial cells [2,3]. Tumoral
expression of both these growth factors has been implicated in
lymphatic metastasis in human breast cancer [4–6]. Earlier we
have shown that overexpression of cyclo-oxygenase (COX)-2, an
inflammation-associated enzyme, upregulated VEGF-C expres-
sion and secretion by human breast cancer cells, thereby
promoting lymphangiogenesis in situ and lymphatic metastasis
[7,8]. Additionally, tumor derived VEGF-C served as an autocrine
stimulus for breast cancer cell migration by binding to a diverse
group of VEGF-C receptors, thus promoting their metastatic
ability by both vascular and lymphatic routes [9]. Many studies
have utilized metastatic variants of breast cancer cell lines to
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35094understand multiple cellular steps and molecular mechanisms
involved in metastasis. MDA-MB-468LN cell line (henceforth
called 468LN cells) was derived as a lymph node metastasizing
variant of the MDA-MB-468GFP human breast adenocarcinoma
cell line (henceforth called 468GFP cells) in the laboratory of one
of the authors (AFC). 468LN cells produced extensive lymph node
metastasis following orthotopic injection in nude mice [10]. They
exhibited increased malignant phenotype in vitro, and overexpres-
sion of a9b1 integrin and its ligand osteopontin, compared with
the parental line. The profound in vitro and in vivo phenotypic and
molecular differences within this pair of cell lines presented a
unique model for elucidating mechanisms in lymph node
metastasis of breast cancer. The integrin a9b1 is a receptor for
extracellular matrix (ECM) proteins such as tenascin and
osteopontin and for the two lymphangiogenic growth factors
VEGF-C and VEGF-D [11]. Overexpression of both osteopontin,
a metastasis-associated molecule [12–14], and its receptor a9b1
may provide the cells with a metastatic advantage. Subsequent
studies revealed some epigenetic signatures of metastasis [15],
distinctive chromosomal aberrations [16] and differential expres-
sion of genes associated with a ‘cancer stem cell-like’ phenotype
[17] in 468LN cells as compared to 468GFP cells. However,
precise molecular mechanisms responsible for the enhanced
lymphatic metastatic ability of these cells remained unclear.
Present study was designed to achieve this goal, demonstrating for
the first time that this ability depended on the differential
expression of a9b1 and its lymphangiogenic ligand VEGF-D by
468LN cells.
In vitro assays for cellular migration and invasion by cancer cells,
and tube formation and migration by endothelial cells, have
provided an opportunity to elucidate autocrine and paracrine
pathways utilized by cancer cells and endothelial cells in
promoting angiogenesis [18–20] and lymphangiogenesis [21–24],
which support metastasis by the vascular and lymphatic routes.
Current study explored whether a differential expression of
VEGF-C or VEGF-D and one or more of the cognate VEGF-
C/D receptors by 468LN cells may contribute to their differential
capacity for lymphatic metastasis by equipping the cells with a
dual advantage: an increase in VEGF-C or -D mediated autocrine
motility by utilizing the cognate receptors; and an increased ability
for inducing lymphangiogenesis in situ by VEGF-C or -D
production and thereby lymphatic metastasis in vivo. This
hypothesis was tested in vitro and in vivo. Initial in vitro studies
compared the expression levels of COX-2 (a VEGF-C/D
upregulating enzyme), VEGF-C and -D, and VEGF receptors
(VEGF-R-2, R-3, a9 integrin) and migratory/ invasive/prolifer-
ative functions in the pair of cell lines (468GFP, 468LN). Since
these studies excluded the roles of COX-2 or VEGF-C but
validated differential expression of a9 integrin and VEGF-D as
well as differential migratory/invasive capacities of 468LN cells,
additional in vitro studies tested (a) the possible dependence of
468LN cell migration/ invasion and migration associated signaling
on a9b1 integrin and its ligand VEGF-C or -D produced by
cancer cells themselves or by macrophages; (b) whether 468LN
cells or their soluble products stimulate tube formation (lymphan-
giogenesis in vitro) and migration/invasiveness of primary human
lymphatic microvascular endothelial cells (HMVEC-dLy) in a
VEGF-D dependent manner. In vivo studies in nude mice used
implants of wild type and a9 or VEGF-D silenced 468LN cells to
compare tumor growth, tumor-induced lymphangiogenesis, an-
giogenesis and metastasis to tumor-draining lymph nodes. We
conclude from our results that a differential capacity for VEGF-D
production and a9b1 integrin expression by 468LN cells provide
an autocrine stimulus for migration/invasiveness and a paracrine/
juxtacrine stimulus for lymphangiogenesis, which jointly contrib-
uted to their profoundly higher ability to metastasize by the
lymphatic route.
Results
Differential migratory, invasive, proliferative and VEGF-D
producing capacity of 486LN cells, as compared to
468GFP cells
In earlier studies 468LN cells were shown to have a higher
proliferative capacity than the parental 468GFP cells [10]. Here
we have confirmed this finding (Fig S1A), and in addition showed
that 468LN cells are more migratory and invasive (Quantification:
Fig 1A; Image: Fig S1B). To investigate the possible mechanism(s)
underlying this differential behaviour, we compared the expression
levels of COX-2, VEGF-A, -C or -D (by RT-PCR, western blots)
in the two cell lines, because COX-2 was identified in our earlier
studies as a migration promoting [7], and VEGF-C upregulating
[9] enzyme. Results (expression of mRNA in Fig 1B, S1C and
protein in 1C) revealed little or no COX-2 expression by either cell
line, but higher levels of VEGF-D expression by 468LN cells.
Other human breast cancer cell lines: MDA-MB-231 [7] and
MCF7-COX-2 (M Majumder 2011, unpublished) served as
positive controls for VEGF-A, -C, -D and COX-2. 468LN cells
secreted significantly higher levels of VEGF-D but not VEGF-C
(Fig 1D) revealed with ELISA. The migration and invasion of
468LN cells but not 468GFP cells was further stimulated in the
presence of exogenous recombinant VEGF-D (rVEGF-D)
(2.5 ng/ml) (Quantification: Fig 1E; Image: Fig S1D).
Reduction of migration/invasiveness and proliferation of
468LN cells by knocking down VEGF-D production
We investigated whether siRNA-mediated knocking down of
VEGF-D could reduce migratory/invasive/proliferative capacity
of 468LN cells. The efficiency of knock down was tested at three
different levels, with qRT-PCR (Fig 2A), western blot (Fig 2B) and
ELISA (Fig 2C). All these parameters showed a significant drop
when cells were transfected with VEGF-D siRNA as compared
with scrambled siRNA (Fig 2: A, B and C). Concomitantly, both
migratory and invasive capacities of 468LN cells were significantly
reduced by silencing VEGF-D (Quantification: Fig 2D; Image:
Fig S2) and restored by addition of exogenous rVEGF-D (2.5 ng/
ml) (Quantification: Fig 2F; Image: Fig S2). These results strongly
support the autocrine migration/invasion promoting role of
endogenous VEGF-D. Similarly, a significant drop in proliferation
resulting from VEGF-D knockdown of 468LN cells (Fig 2E)
indicated additional proliferation-promoting role of endogenous
VEGF-D.
Expression of VEGF-D-binding receptors by 468LN cells
The biological actions of VEGF-D can be mediated theoreti-
cally through two tyrosine kinase receptors VEGFR-2 [25] and
VEGFR-3 [26] and a9b1 integrin [11]. To determine which of
these receptors was responsible for the autocrine effects of VEGF-
D, we analysed both mRNA and protein expression of these
receptors in 468GFP and 468LN cells, along with other human
breast cancer cell lines: MDA-MB-231 [9] and MCF7-COX-2 (M
Majumder 2011, unpublished) served as positive controls for
VEGF-R2 and VEGF-R3 expression. As reported earlier [9,10],
468LN cells expressed high levels of a9b1 integrin. Of all the
receptors investigated, differential expression of a9 in 468LN cells
was most significant at both mRNA (Fig 3: A, B) and protein
(Fig 3C) levels.
a9b1-VEGF-D Co-Expression and Lymphatic Metastasis
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hinders migratory and invasive functions of 468LN cells
and a9-associated signaling
Autocrine Regulation: First, we tested whether a mouse
monoclonal a9b1 blocking antibody (1 and 5 mg/ml, added to
cells 0.5 h prior to and during these assays) could impair 468LN
cell migration and invasiveness. This antibody had been shown to
inhibit VEGF-C/-D induced migration of a9 transfected mouse
embryonic fibroblasts and primary adult human dermal micro-
vascular endothelial cells [11]. Both migration and invasion
(Fig 4A) of 468LN but not 468GFP cells (data not shown) were
significantly inhibited in the presence of the a9b1 blocking
antibody (5 mg/ml) as compared to control IgG (5 mg/ml). This
inhibition could not be reversed by addition of rVEGF-D (2.5 ng/
ml) (Fig 4A). Second, we tested whether silencing a9 integrin gene
could impair migration/ invasiveness of 468LN cells. Cells were
transfected with a9 siRNA (1 mM) and the following four
parameters were measured: a9 mRNA level (Fig 4B), a9 protein
level (Fig 4C), cellular migration (Quantification: Fig 4D; Image:
Fig S3), and invasion (Fig 4D). We observed a significant drop in
each of the parameters, when a9 integrin transfected cells were
compared with scrambled siRNA treated cells. This inhibition
could not be reversed by addition of rVEGF-D (Quantification:
Fig 4E; Image: Fig S3), validating that a9 was the dominant
receptor for VEGF-D action in these cells. Since Erk activation is a
key signaling pathway mediated by a9 interaction with VEGF-D
[11], we compared Erk phosphorylation in wild type and a9-
silenced 468LN cells in the absence or presence of VEGF-D. The
phosphorylation level was significantly suppressed by a9 knock-
down which could not be restored with rVEGF-D (Fig 4F). These
results taken together, affirm the autocrine role of VEGF-D
interacting with a9b1 integrin in promoting migration and
invasion of 468LN cells.
Paracrine Regulation: Tumor-associated macrophages have
been reported to stimulate tumor progression and metastasis by
producing soluble factors including VEGF-C and D [27]. VEGF-
C and -D production by macrophages also contributes to
Figure 1. Differential migratory, invasive, and VEGF-D producing capacity of 486LN cells, as compared to 468GFP cells: (A)
Compared to 468GFP cells, 468LN cells were significantly more migratory and invasive. (B, C) 468LN cells expressed significantly higher level of VEGF-
D mRNA measured with semi-quantitative RT-PCR (B) and total protein measured with western blot (C), compared to 468GFP cells. (MDA-MB-231 and
MCF7-COX-2 cells served as positive controls for COX-2 and VEGF-C/D). (D) 468LN cells secreted significantly higher levels of VEGF-D but not VEGF-C,
in comparison to 468GFP cells as measured by ELISA in cell supernatants; MDA-MB-231 cells served as positive controls for both VEGF-C and VEGF-D.
(E) Exogenous rVEGF-D (2.5 ng/ml) increased both migration and invasion of 468LN, but not 468GFP cells. Migration/ invasion indices were
normalized relative to 468GFP in SFM. Migration and invasion of 468GFP-SFM in Fig E was performed separately from the data in Fig A. All bars
represent mean (n=4) +/2 S.E, *, P, 0.05; **, P, 0.01.
doi:10.1371/journal.pone.0035094.g001
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role of VEGF-C or -D producing tumor-associated macrophages
in situ in promoting a9-dependent motility or invasiveness of
468LN may also contribute to their lymphatic metastatic
phenotype. We tested this possibility by utilizing a VEGF-C and
-D producing surrogate macrophage cell line RAW 264.7. We
observed markedly increased migration and invasiveness of 468LN
cells when macrophage cell-conditioned medium was placed in the
bottom chamber. This increase was significantly abrogated by
siRNA mediated knockdown of a9 in 468LN cells in comparison
with scrambled siRNA treated cells (Quantification: Fig 5; Image:
Fig S4).
VEGF-D production by 468LN cells increases capillary-like
tube formation by HMVEC-dLy cells via paracrine and
juxtacrine mechanisms
In vitro lymphangiogenesis assays utilize the formation of three-
dimensional tube or vessel like structures by lymphatic endothelial
cells [29–31]. Cancer cells can also form pseudo-vascular tubes on
Matrigel, the phenomenon known as vascular mimicry [32,33],
the temporal kinetics of tube formation differing from cell to cell
[34,35]. Upon plating serum-starved cells on growth factor
reduced Matrigel we noted that both 468LN and HMVEC-dLy
cells could individually form tube like structures, but with different
kinetics. HMVEC-dLy cells formed tubes as early as 8 h (Fig 6: B,
J) whereas 468LN cells required 12 h or more to show the earliest
signs of tubulogenesis, at which time no tubulogenesis was evident
with 468GFP cells (not shown). We tested the paracrine role of
468LN cells for lymphangiogenesis via VEGF-D production,
measured with tube formation by HMVEC-dLy cells in the
presence of 468LN conditioned medium. In addition, possible
juxtacrine effects (defined as the local effects of a cell membrane
bound molecule on another cell nearby) of 468LN cells on tube
formation by HMVEC-dLy cells were tested in co-cultures of
cancer cells and HMVEC-dLy cells.
Co-culture: When HMVEC-dLy cells were co-cultured with
cancer cells on Matrigel at 1:1 cell ratio, tubes formed as early as
4 h with 468LN cells (Fig 6: C, K) and the number of tubes and
branching points were significantly higher compared to co-culture
with 468GFP cells at both 4 h and 8 h (Image: Fig 6 A, I;
Quantification: Q, R) or those in HMVEC-dLy cells cultured
alone (Fig 6: B, J). From images of tubes in co-culture, it was
evident that both lymphatic endothelial and GFP-marked cancer
Figure 2. Reduction of migration and invasion of 468LN cells by knocking down VEGF-D production:( A–C) Levels of VEGF-D knock
down in 468LN cells was confirmed by three different methods, (A) qRT-PCR, (B) western blot and (C) ELISA. After VEGF-D knock down (KD) in 468LN
cells, (D) migration, invasion and (E) proliferation significantly dropped as compared to scrambled knock down (SCR-KD) cells. (F) Addition of
exogenous rVEGF-D or FBS increased both migration and invasion of VEGF-D knocked down 468LN cells. Bars represent mean (n=4 in all cases
except C,n=6 )6 SE, *,P,0.05; **,P,0.01.
doi:10.1371/journal.pone.0035094.g002
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indicating cell-cell interaction or collaboration in tube formation.
When VEGF-D was knocked down in 468LN cells, tube formation
in co-cultured cells were reduced but not completely abolished
(Fig 6: E, M) in comparison with those in co-cultures including
scrambled siRNA treated tumor cells (Image not shown;
Quantification: Fig 6: Q, R). Cells regained their tube forming
capacity when rVEGF-D (2.5 ng/ml) was added to the medium
(Image: Fig 6 G, O and Quantification: Q, R). Again the GFP
marker in 468LN cells confirms that these tubes were not exclusive
to HMVEC-dLy cells (Fig 6: D, F, H, L, N, P). We speculate that
the VEGF-D mediated enhancement of lymphangiogenesis in co-
cultures represents a juxtacrine effect of cancer cells. In other
words, binding of tumor-derived VEGF-D to a9 integrin receptor
on cancer cells leaves its VEGF-R3 binding site unoccupied, so
that the same VEGF-D molecule can also bind to VEGF-R3
expressed by HMVEC-dLy cells to mediate the lymphangiogenic
stimulus.
468LN Conditioned Medium: Next, we investigated the
paracrine effect of VEGF-D produced by 468LN cells on tube
formation by HMVEC-dLy cells. Briefly, 468LN and 468GFP
cells (used as control) were grown for 24 h in regular medium, and
serum-starved for another 12 h to collect the conditioned medium.
This conditioned medium was added to HMVEC-dLy cells and
plated on Matrigel. As observed previously in co-culture,
HMVEC-dLy cells formed tubes with an accelerated tempo at
both the time points 4 h and 8 h (Image: Fig 7 B, F and
Quantification: I, J) in the presence of 468LN CM compared to
468GFP CM, validated by the number of tubes and branching
points (Image: Fig 7 A, E and Quantification: I, J). To test the role
of VEGF-D as a secreted product of 468LN cells in the induction
of tube formation by HMVEC-dLy cells, the same experiments as
above were duplicated after siRNA mediated VEGF-D knock
down of 468LN cells. Tube formation at both the time points, with
CM from VEGF-D silenced 468LN cells, was significantly reduced
but not completely abolished when compared to scrambled siRNA
knock down (Image: Fig 7 C, G and Quantification: Fig I, J). This
can be explained by the presence of other stimulants present in
growth factor reduced Matrigel or other products secreted by the
cells. Again, addition of exogenous rVEGF-D (5 ng/ml) promoted
tube formation (Image: Fig 7 D, H and Quantification: I, J). The
above results taken together confirmed the paracrine and
juxtacrine roles of 468LN cells on lymphangiogenesis resulting
from VEGF-D production.
VEGF-D secreted by 468LN cells promotes migration and
invasion by HMVEC-dLy cells
Since lymphatic endothelial cell migration and invasion of
basement membranes are essential steps for lymphangiogenesis in
vivo [36], we examined the paracrine effect of VEGF-D secreted by
468LN cells in promotion of migratory and invasive functions of
HMVEC-dLy cells. 468LN cells (added in the bottom chamber)
were found to stimulate migration as well as invasion (Image:
Fig S5; Quantification: Fig 8) of HMVEC-dLy cells compared to
468GFP cells added to the bottom chamber. When similar
experiments were done using VEGF-D-silenced 468LN cells in the
bottom chamber following transfection with VEGF-D siRNA
(5 mM), the migration and invasiveness of HMVEC-dLy cells was
lower than those observed with un-manipulated 468LN cells
(Image: Fig S5; Quantification: Fig 8). More interestingly, this
reduction could be abrogated with addition of exogenous r-VEGF-
D to the VEGF-D silenced 468LN cells (Image: Fig S5;
Quantification: Fig 8). These results further define the cellular
steps underlying the paracrine role of 468LN cell-derived VEGF-
D in promoting lymphangiogenesis.
Figure 3. Expression of VEGF-D-binding receptors by 468LN cells: (A) Expression of VEGF-R2 and R3 mRNA examined with semi quantitative
RT-PCR, and (B) a9 integrin mRNA measured with qRT-PCR. (C) Confirmation of VEGF-R2, VEGF-R3, and a9 integrin expression at protein levels by
western blot. MDA-MB-231 and MCF7-COX-2 cells were used as positive controls primarily for VEGF-R2 and VEGF-R3 expression. Differentially high a9
integrin expression by 468 LN cells was evident. Bars represent mean (n=4) 6 SE, *,P,0.05.
doi:10.1371/journal.pone.0035094.g003
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Since mitogen-activated protein kinases (MAPKs) have been
implicated in VEGF-stimulated migration in a variety of cell types
[37,38], HMVEC-dLy cells were stimulated with 20 ng/ml r-
VEGF-D for 15–60 minutes and processed for western blots.
Phosphorylation of Erk1/2 was induced by recombinant VEGF-D
(r-VEGF-D), reaching maximal activation at 60 minutes (Fig 9A).
Pretreatment with Erk1/2 inhibitor U0126 (10, 15 mM) for
60 minutes completely blocked Erk phosphorylation which could
not be restored by addition of r-VEGF-D (Fig 9A). Furthermore,
migration stimulation of HMVEC-dLy cells with rVEGF-D was
significantly compromised by pretreating the cells with U0126 at a
concentration as low as 5 mM (Image: Fig S6; Quantification:
Fig 9B).
Experimental design in vivo
We tested the individual contributions of VEGF-D and a9
integrin to the lymphatic metastatic phenotype of 486LN cells in
vivo by stably knocking down either molecule with shRNA
plasmids. In vivo experiments were performed with these two
stable cell lines named Da9/468LN and DVEGF-D/468LN for a9
integrin and VEGF-D stable knock down respectively. Since
control shRNA knock down showed no difference in protein
expression when compared to parental 468LN cells (Fig S7), we
conducted in vivo experiments with parental 468LN cells as positive
control for VEGF-D and a9b1 integrin expression. Tumor
growth, lymphatic ingrowth into the tumors, intratumoral
lymphangiogenesis as well as angiogenesis, and lymphatic
metastasis were measured after subcutaneous implantation of
tumor cells suspended in growth factor reduced Matrigel. This
implantation method allowed ingrowths of capillaries and
lymphatics into the developing tumors from pre-existing vascula-
Figure 4. Blockade of a9b1/VEGF-D interaction hinders autocrine migratory/invasive functions of 468LN cells and a9-associated
signaling: (A) A strong inhibition of both migration and invasion indices of 468LN cells, noted with a9b1 blocking antibody (5 mg/ml). This inhibition
could not be reversed by addition of rVEGF-D. Data were normalized to control IgG for a9b1 blocking antibody (ab) and to a9b1 blocking antibody
treated cells for rVEGF-D. Knock down of a9 was validated with qRT-PCR (B) and western blot (C). (D) Knock down of a9 integrin (a9-KD) significantly
compromised both migration and invasion of 468LN cells compared to scrambled knock down (SCR-KD) cells. (E) Following a9-KD, but not SCR-KD,
migratory and invasive functions could be stimulated with FBS, but not with rVEGF-D. Data presented as the mean (n=4 except invasion data in D,
n=6)6 SE. *, P,0.05; **,P,0.01. (F) Phospho Erk1/2 was measured using western blots in wild type and a9-silenced, serum starved (24 h) 468LN
cells in the presence or absence of rVEGF-D (3 mg/ml) at 0–60 min as compared to total Erk1/2. Significant constitutive Erk1/2 activity noted in the
absence of rVEGF-D was stimulated further in the presence of rVEGF-D at 15–45 min (peak shown at 45 min). Knock down of a9 integrin resulted in
suppressed Erk1/2 activity in both cases.
doi:10.1371/journal.pone.0035094.g004
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controls.
VEGF-D knock down reduces lymphatic ingrowths into
the tumor
Evans Blue dye injection sites were approximately 2 cm apart
from the tumor implants, allowing a visual tracing of lymphatics
into both 468LN and DVEGF-D/468LN tumors (Fig 10: A, E).
Significant infiltration of blue dye in 468LN tumor (Fig 10: B, C)
and tumor-draining lymph node (Fig 10: B, D) was observed at
10–15 minutes post injection. In contrast, no dye was visible in
DVEGF-D/468LN tumors even at 25 minutes (Fig 10: F, G). In
DVEGF-D/468LN implanted mice, it was hard to visualise
draining lymph nodes from the surface because of lack of staining
with blue dye, so that no image could be presented.
Knock down of a9 integrin and VEGF-D in 468LN cells
abrogates primary tumor growth in nude mice
Implants of Matrigel alone at four locations (two inguinal, two
axillary) in one mouse remained unchanged in size (Fig 11A),
serving as negative control. Tumor growth rates given by
externally measured volumes (Fig 11B) at days 12, 15, 18 and
weights taken at sacrifice on day 20 (Fig 11C) were drastically
lower (p,0.001) in mice implanted with Da9/468LN and
DVEGF-D/468LN cells compared to 468LN cell implanted mice
(gross morphology of representative tumors and lymph nodes in
Fig 11A). Tumors from Da9/468LN and DVEGF-D/468LN cells
implanted mice were indistinguishable (p.0.07) from Matrigel
alone, indicating a complete abrogation of growth.
Metastatic ability to the draining lymph node was
abrogated by a9 integrin and VEGF-D knock down in
468LN cells
In frozen sections of lymph nodes draining 468LN tumors,
many green 468LN cells (resulting from the GFP marker) were
identified by fluorescence microscopy (Fig 12A). In contrast, such
cells were hardly visible in the draining lymph nodes from both
Da9/468LN and DVEGF-D/468LN tumors, indicating that
cancer cells lost their ability to metastasize to the nodes. In an
additional approach, we indirectly quantified metastasis using
human mitochondrial marker (MTCO2) RNA (Fig 12B) and
protein (Fig 12C) expression levels in lymph nodes. Both qRT-
PCR and western blots confirmed the abundance of human cancer
cell related marker in nodes draining 468LN tumors. Based on the
standard plot obtained with predetermined numbers of 468LN
cells expressing human mitochondrial marker MTCO2 measured
with qRT-PCR (Fig S8), we approximated that on the average
2,000 468LN cells metastasized to the individual 468LN tumor
draining lymph node. In contrast, they were undetectable
(compared to the back ground given by Matrigel implant) in
lymph nodes draining Da9/468LN and DVEGF-D/468LN
tumors.
Ability to induce intra-tumoral lymphangiogenesis is
abrogated by both VEGF-D and a9 integrin knock down
in 468LN cells
Indirect Measurements. To quantify the relative
abundance of mouse lymphatics within the human tumor
transplants we took advantage of the mouse lymphatic
endothelial marker LYVE-1 at protein and mRNA levels. We
observed significant reduction in mouse LYVE-1 expression at
both mRNA (p,0.05) (Fig 13A) and protein levels (Fig 13B) in
both Da9/468LN and DVEGF-D/468LN tumors compared to
468LN tumors.
Direct Measurements. In addition to the quantification of
LYVE-1 at the mRNA and protein levels, we directly measured
the levels of lymphangiogenesis and angiogenesis in serial frozen
sections of tumors with immunofluorescent labelling for LYVE-1
(red) and CD31 (red) respectively. CD31 staining for blood vessels
(angiogenesis) was also quantified, since it is one parameter that
can dictate growth of solid tumors. The immunofluorescence
images are representative of ‘‘hot spots’’ within the tumors [39,40].
High levels of tumor-associated angiogenesis as well as
lymphangiogenesis (Fig 14A, and quantified in Fig 14B)
occurred in 468LN implanted tumors. These events were nearly
completely abrogated in Da9/468LN and DVEGF-D/468LN
implants. No measurable angiogenesis or lymphangiogenesis was
observed in Matrigel only implants (data not shown).
Discussion
Since its isolation, the 468LN cell line was shown to be a lymph
node metastasizing variant of the MDA-MB-468 human breast
adenocarcinoma cell line with increased in vitro proliferative
capacity and overexpression of a9b1 integrin and osteopontin
[10]. While earlier studies revealed multiple mechanisms under-
lying their metastatic phenotype [15,16,17], the precise molecular
mechanism(s) responsible for their increased lymphatic metastatic
ability remained undefined. In the present study, utilizing multiple
in vitro and in vivo assays, we have dissected the mechanisms
underlying the capacity of the cells in promoting lymphangiogen-
esis, lympho-vascular invasion and lymphatic metastasis. We have
excluded the differential role of COX-2 expression in VEGF-C or
D upregulation and show that differential overexpression of a9b1
and its ligand VEGF-D by 468LN cells underlie these events.
Screening of several human breast cancer cell lines revealed that
468LN cells express the highest level of both markers (Fig S9).
However, another cell line, MDA-MB-231, also known for its
ability for lymphatic metastasis, expresses both these markers. This
observation suggests that these markers may also contribute to
lymphatic metastasis in addition to the earlier reported COX-2
Figure 5. Paracrine migration/invasion promoting role of
macrophage derived factors on 468LN cells is largely a9
dependent: Conditioned medium (CM) of RAW 264.7 macrophage
cells strongly stimulated both migration and invasiveness of 468LN
cells. This stimulation was significantly abrogated by knocking down
the a9 integrin (a9-KD) in 468LN cells, as compared to scrambled siRNA
knock down (SCR-KD) cells. The knockdown of a9 integrin was done as
in Fig 4. Data presented as the mean (n=4) 6 SE. *, P,0.05; **,P,0.01.
doi:10.1371/journal.pone.0035094.g005
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diversity of in vitro derived cell lines may reflect the tumor cell
heterogeneity with some degree of clonal dominance in situ in
advanced cancers, we suggest that present results are clinically
relevant. We show that dual over expression of a9b1 integrin and
its ligand VEGF-D by 468LN cells lead to multiple mechanisms in
promoting lymphatic metastasis. While VEGF-D production
accounted for their robust ability to induce lymphangiogenesis in
vitro and in vivo, its interaction with a9b1 equipped them with an
autocrine stimulus for motility and invasiveness, which represent
key steps in the process of metastasis by both vascular and
lymphatic routes. Furthermore, tumor-derived VEGF-D served
both as a paracrine as well as a juxtacrine stimulus for tumor-
induced lymphangiogenesis. Finally, our in vivo studies in nude
mice confirmed the obligatory roles of both a9 integrin receptor
and its ligand VEGF-D in promoting tumor-associated lymphan-
giogenesis and lymphatic metastasis. Present study, to our
knowledge, is the first report of a dual role of this receptor-ligand
interaction in human breast cancer, in events associated tumor
growth and metastasis, in particular, with a lymphatic metastatic
phenotype.
We have employed multiple in vitro and in vivo approaches,
which complement one another for unveiling mechanisms. In vitro
approaches included proliferation, migration, invasion assays for
tumor cells revealing autocrine stimulation by endogenous VEGF-
D. To test and dissect the paracrine and juxtacrine roles of VEGF-
D produced in the tumor micro-environment, we employed
HMVEC-dLy cells in a number of in vitro assays: tube formation,
migration and invasion of the ECM, which are recognized as key
steps for angiogenesis and lymphangiogenesis. In all cases the
stimulation provided by tumor cell-conditioned medium or co-
culture with tumor cells was attenuated by knocking down VEGF-
D, and the stimulation could be restored with exogenous VEGF-
D. In co-culture experiments the role of tumor cell-derived VEGF-
Figure 6. VEGF-D production by 468LN cells increased capillary-like tube formation of HMVEC-dLy cells: 468GFP cells when co-
cultured with HMVEC-dLy cells formed sparse and incomplete tube like structure at either 4 h (A)o r8h( T), which were not different from HMVEC-
dLy cells alone at both 4 h (B) and 8h (J) when seeded on growth factor reduced Matrigel in serum free medium (SFM). When 468LN cells were co-
cultured with HMVEC-dLy cells, they showed enhanced formation of complete tubes as early as 4 h (C) and 8 h (K). (D, L) 468LN cells express GFP, so
that it was evident from the images of tubes in co-culture, that both cancer cells and HMVEC-dLy cells aligned together in forming tubes, indicating
cell-cell interaction or collaboration in aligned tube formation. (E, M) To test whether 468LN cell-derived VEGF-D contributed to tube formation by
HMVEC-dLy cells, the same experiments were done after silencing the endogenous VEGF-D of 468LN cells. In this case, tube formation in co-cultured
cells were reduced but not completely abolished. (G, O) Cells regained their tube forming capacity, when rVEGF-D (2.5 ng/ml) was added to the
medium. (F, H, N, P) Again the GFP marker in 468LN cells confirms that these tubes were not exclusive to HMVEC-dLy. Quantitative data presented
as (Q) tube number and (R) branching point indices. Data represent (n=3) 6 SEM. *,P,0.05; **,P,0.01.
doi:10.1371/journal.pone.0035094.g006
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interpreted as a juxtacrine regulation (Fig 15). As noted in the
present study, an alignment of two partners was also reported
during tube formation by coculturing HUVEC cells with a brain
cancer cell line [41]. We suggest that this alignment demonstrated
in vitro is an indicator of close physical association of the partners
allowing for a juxtacrine stimulation of lymphatic and blood
capillary growth by recruitment of endothelial cell precursors.
The in vivo studies of lymphangiogenesis utilized three different
approaches: Evans blue dye tracing, quantification of LYVE-1
marker at the mRNA and protein levels, and identification of
lymphatic vessels by immunofluorescence. The in vivo studies on
lymphatic metastasis utilized two different approaches: the
presence of human mitochondrial marker MTCO2 and the
GFP marker. Our in vivo results clearly indicate that VEGF-D is a
key lymphangiogenic factor for lymphangiogenesis on its own and
abrogation of expression of either VEGF-D or its receptor a9
integrin could completely eradicate lymphangiogenesis and
lymphatic metastasis. A concomitant reduction in tumor growth
by VEGF-D knock down can be attributed to the autocrine
proliferation stimulating role of VEGF-D shown in vitro. The fact
that a9 integrin knock down alone was equally efficient as VEGF-
Figure 7. 468LN cell conditioned medium increases capillary-like tube formation by HMVEC-dLy cells: (A, E) HMVEC-dLy cells could
hardly form any tube like structure with addition of conditioned medium (CM) from 468GFP cells at (A) 4 h and (E) 8 h. (B, F) HMVEC-dLy cells could
form complete tubes as early as at (B) 4 h and (F) 8 h with 468LN CM. (C, G) VEGF-D knock down (KD) in 468LN cells, resulted in reduction in tube
formation at both time points. (D, H) Again, addition of rVEGF-D in the CM of VEGF-D-KD 468LN cells stimulated tube formation. (I, J) Quantitative
data for above observations are presented as (I) tube number index and (J) branching point index showing significant increase in tube and branch
formation in presence of 468LN cell CM, but not 468GFP CM. Moreover VEGF-D KD in 468LN cells could block this function and HMVEC-dLy cells
regained this function when rVEGF-D was added. Data represent mean (n=3) 6 SE. *,P,0.05; **,P,0.01.
doi:10.1371/journal.pone.0035094.g007
Figure 8. VEGF-D secreted by 468LN cells promotes migration
and invasion by HMVEC-dLy cells: Significant stimulation of both
migration and invasion of HMVEC-dLy cells occurred in the presence of
468LN conditioned medium (CM), as compared to 468GFP CM. This
stimulation was significantly attenuated by VEGF-D knock down (KD) in
468 LN, which could be restored with exogenous rVEGF-D. For VEGF-D
knock down, data were normalised to scrambled siRNA (SCR-KD), and
for rVEGF-D stimulation, data were normalised to VEGF-D knock down.
Data represent mean (n=4) 6 SE. *,P,0.05; **,P,0.01.
doi:10.1371/journal.pone.0035094.g008
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metastasis reinforces the juxtacrine role of a9b1 bound VEGF-D,
which can additionally bind to VEGF-R3 expressed by lymphatic
endothelial cells to stimulate the cellular steps in lymphangiogen-
esis (Fig 15).
In our earlier studies with human breast cancer [7,8,9], we
identified the potential roles of COX-2, VEGF-C and a diverse
family of VEGF-C binding receptors for lymphangiogenesis and
lympho-vascular invasion. The present study shows that COX-2
independent overexpression of VEGF-D can play an equally
important role in these events, and a9b1 integrin represents an
important lymphangiogenic receptor as well as a receptor for
autocrine motility in cancer cells. The migration and invasion-
stimulating role of endogenous VEGF-D in 468LN cells was
demonstrated by silencing VEGF-D gene. The obligatory role of
a9b1 integrin as the dominant receptor of this ligand for
mediating these functions was demonstrated by using a9b1
blocking antibody as well as silencing of the a9 gene in cancer
cells. Furthermore, silencing of a9 was shown to suppress both
native and VEGF-D stimulated Erk1/2 phosphorylation, a key
signaling event in a9-VEGF-D interaction [11]. Autocrine actions
of VEGF-C and VEGF-D including their ability to stimulate
cellular migration has been documented in other cell types, for
example, Kaposi’s sarcoma cells [42] and lung cancer cells [43] in
conjunction with receptors like VEGFR-2 and VEGFR-3.
Overexpression of a9b1 integrin in 468LN cells appears to
provide a metastatic advantage by virtue of overexpression of at
least two ligands, osteopontin and VEGF-D. This integrin (also
known as VLA-9) is a key receptor involved in leukocyte migration
[44], due to interaction with multiple ligands including osteopon-
tin [45]. Since osteopontin, a metastasis promoter protein [46] and
a marker of human breast cancer progression [14,47,48], is over-
expressed in 468LN cells, this ligand may present an additional
autocrine pathway for metastasis, at least in part by interaction
with a9b1 via the RGD domain [14]. The important role of a9b1
as a lymphangiogenic receptor because of its binding to VEGF-C
and VEGF-D has been well established [11]. This function
explains why homozygous null mutation of the a9 gene causes
congenital chylothorax in the murine fetus [49]. Tumoral
expression of a9b1 showed a significant association with reduced
overall patient survival and with distant-metastasis-free survival
[50]. The ability of a9b1 to bind VEGF-A can also contribute to
angiogenesis [51,52], as also documented by reduced tumor-
associated angiogenesis by a9 knock down in our in vivo studies.
Interestingly, another a9b1 ligand tenascin, an ECM protein, was
reported to be a stromal marker for malignancy in mammary
epithelium [53]. Thus expression of a9b1 by breast cancer cells
and presence of any of the above ligands in the tumor
microenvironent could increase their migratory or invasive
capacity to promote metastasis by both vascular and lymphatic
routes. For example, host macrophages, which are known to be a
rich source of both VEGF-C and VEGF-D during inflammation
[28] as well as tumor growth [27], could have a paracrine effect on
cancer cells in promoting metastastic phenotype. Indeed, we found
that the conditioned medium from the VEGF-C and VEGF-D
producing macrophage cell line RAW 264.7 strongly stimulated
migration and invasiveness of 468LN cells, and this stimulation
was largely abrogated in a9 silenced cells. Furthermore, genetic
Figure 9. VEGF-D induced migration of HMVEC-dLy cells is Erk dependent: (A) Cells were serum starved for 24 h before stimulation with r-
VEGF-D (20 ng/ml) for varying lengths of time (0, 15, 30 and 60 minutes) or pre-treated with varying concentrations of Erk inhibitor U0126 (0, 5, 10
and 15 mM) for one hour and further treated with 20 ng/ml r-VEGF-D for 30 minutes. Cell lysates were prepared and analyzed by western blot for
Erk1/2 activity. VEGF-D stimulated Erk activation in HMVEC-dLy cells and this stimulation was prevented by pre-treatment with U126. (B) Cell
migration was quantified by transwell migration assays; VEGF-D stimulated migration was inhibited with U126 (5–15 mM). 2% FBS served as a positive
control. Migration data were represented as a mean 6 S.E. for three independent experiments (n=3). For recombinant VEGF-D stimulation, data were
normalised to SFM and for Erk inhibition data were normalised to r-VEGF-D stimulation.
doi:10.1371/journal.pone.0035094.g009
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giogenesis and lymphatic metastasis in vivo affirming the key role of
this receptor in these events possibly utilising multiple ligands
produced by the tumor as well as host cells.
We have previously shown that COX-2 mediated VEGF-C
upregulation in human breast cancer cell lines [7,9] confers a
prometastatic phenotype by two mechanisms: increased ability for
inducing lymphangiogenesis in situ [9] and an autocrine
stimulation of motility by utilizing a diverse family of VEGF-C
receptors [8]. VEGF-D can now be added to VEGF-C as a
partner in promoting lymphatic metastasis in human breast cancer
by utilizing the same mechanisms. Peritumoral lymph vessel
density in invasive lobular breast cancer was correlated with
VEGF-D expression by cancer cells and lymph node metastasis
[54]. VEGF-D, which can bind to both VEGFR-2 and VEGFR-3,
was shown to be capable of inducing both angiogenesis and
Figure 10. VEGF-D knock down reduced lymphatic ingrowths into the tumor: (A) Digital camera captured picture at 5 minutes show the
Evans blue dye injection sites and the dye stained lymphatics going towards the 468LN tumor (T). (B) Images were captured at 15 minutes using a
dissection microscope. These images show lymphatics (arrows) going into the 468LN tumors as well as tumor draining axillary lymph nodes (LN). (C)
Image of same tumor at a higher magnification (see inset) captured at 20 minutes showing blue dye inside the tumor (T), and (D) inside the lymph
node (LN) at a higher magnification (see inset). (E) In contrast, VEGF-D knock down (DVEGF-D/468LN) tumor implants showed very few lymphatics
traceable from the injection site captured with a digital camera. (F) Picture taken at 15 minutes showing lymphatics alone but very little dye in the
tumor. (G) Even at 25 minutes no dye-stained lymphatics was visible on the surface or inside the tumor at a higher magnification (see inset).
doi:10.1371/journal.pone.0035094.g010
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mice transplanted with a tumor cell line forced to over-express
VEGF-D, but not VEGF-A. The lymphatic spread by the VEGF-
D expressing line could be blocked with a VEGF-D specific
antibody [55]. We could block every event in tumor progression
by either VEGF-D or a9 knock down, such as tumor growth,
tumor associated lymphangiogenesis, angiogenesis, and lymphatic
metastasis, indicating the independent as well as combined roles of
the ligand and the receptor in cancer progression in vivo. The
independent role of this receptor in the present cell line can be
attributed to the paucity of expression of an alternate lymphangio-
genic receptor such as VEGF-R3 (Fig 3A). The independent role
of this ligand suggests the importance of the demonstrated
autocrine, paracrine and proposed juxtacrine roles of VEGF-D
(Fig 15). Furthermore, angiogenic ability of VEGF-D by binding
to VEGF-R2 on endothelial cell precursors [55] may explain
reduced tumor associated angiogenesis in vivo following VEGF-D
knockdown. While VEGF-D expression was reported to be
associated with poor prognosis in human breast cancer [56], the
prognostic role of the combined expression of a9 integrin and
VEGF-D in human breast cancer remains to be investigated.
In conclusion, our combined in vitro and in vivo results with the
MDA-MB-468LN breast cancer cell line revealed that key events
such as lymphangiogenesis, lympho-vascular invasion and lym-
phatic metastasis can be triggered by highly aggressive breast
cancer cells themselves, in addition to host cells within the tumor
micro-environment, involving autocrine, paracrine and juxtacrine
pathways.
Ethics Statement
N/A
Materials and Methods
Cell lines
Human breast cancer cell lines MDA-MB-468GFP and MDA-
MB-468LN were used from the original stock shortly after their
generation [10]. Human MDA-MB-231, SK-BR-3, Hs578T,
T47D, MCF-7 breast cancer cell lines and mouse macrophage
RAW 264.7 cell line were purchased from ATCC (Manassas, VA).
Human MCF7-COX-2 breast cancer cell line was generated in
our laboratory by stable transfection of MCF-7 cells with COX-2
cDNA cloned into the eukaryotic expression vector pIRES2-
EGFP (M Majumder 2011, unpublished). MDA-MB-468GFP and
468LN cells were grown in a-MEM; MDA-MB-231, Hs578T,
T47D, and RAW 264.7 were maintained in DMEM (GIBCO/
Invitrogen), MCF7-COX-2 and SK-BR-3 were grown in EMEM
and McCoy’s 5A (ATCC), respectively. All cell lines were grown as
a monolayer in basal medium supplemented with 10% FBS,
50 U/ml penicillin and 50 mg/ml streptomycin (GIBCO/Invitro-
gen). Medium for MCF7-COX-2 cells was supplemented with
0.01 mg/ml bovine insulin and 500 mg/ml Gentamicin (Invitro-
gen). Primary human dermal lymphatic microvascular endothelial
Figure 11. Knock down of a9 integrin and VEGF-D in 468LN cells reduced primary tumor growth in nude mice: (A) Representative
images of tumors and Matrigel alone as well as the draining lymph nodes on day 20 (a scale in mm shown in the background). (B) Tumor growth
rates determined by volume measured externally were dramatically reduced in both a9 integrin (Da9/468LN) and VEGF-D knock down (DVEGF-D/
468LN) tumors (indistinguishable from Matrigel alone). (C) Tumors were excised and mean weights of tumors and Matrigel were retrieved on day 20.
Weights of 468LN tumors were significantly higher than those of Matrigel alone or Da9/468LN and DVEGF-D/468LN tumors. Data represented as
means (n=16 for tumors and 4 for Matrigel) 6 S.E. *p,0.05, **p,0.001.
doi:10.1371/journal.pone.0035094.g011
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2-MV BulletkitH (CC-3202, LONZA), for initial expansion.
Subsequent passages were done according to the manufacturer’s
protocol. HMVEC-dLy cells at seventh passage were used for in
vitro tube formation, migration, and invasion assays under growth
conditions as specified later.
Transfection of cells with siRNAs and shRNA plasmids
All in vitro experiments were performed with transiently siRNA
transfected cells and all in vivo experiments with shRNA plasmids
stable transfected 468LN cells. Cells were grown in 6-well plates in
antibiotic-free medium, plated overnight at 37
uC, 5% CO2 and
then transfected with 1–5 mM of either non-targeting siRNA
(scrambled siRNA) or siRNA targeting VEGF-D (s5203) and a9
(s7554) (Ambion, Applied Biosystems) with AmaxaH Cell Line
NucleofectorH Kit V, according to the manufacturer protocol
(LONZA). The transfection efficiency was validated by qRT-PCR,
western blot, and also by ELISA for VEGF-D. We established
stable VEGF-D and a9 integrin knock down 468LN cell lines
using shRNA plasmids (h) [VEGF-D (sc-39844-SH, a9 integrin
(sc-35674-SH) and control (sc-108060), from Santa Cruz Biotech-
nology, CA]. After transfection (with 10 mg of respective plasmids),
cells were grown in a-MEM medium supplemented with 10% FBS
and antibiotic selection started 48 h post transfection with
puromycin dihydrochloride 3 mg/ml (sc-108071, Santa Cruz
Biotechnology, CA). After 3–4 weeks, puromycin-resistant colonies
were selected and measured for VEGF-D and a9 integrin
expression by qRT-PCR and western blot. The VEGF-D and
a9 integrin silenced clones were named as DVEGF-D/468LN and
Da9/468LN and maintained in a-MEM supplemented with 10%
FBS in the presence of 500 mg/ml puromycin.
Real time RT-PCR
Total RNA was isolated from cancer cells, human lymphatic
cells, tumor tissues and lymph nodes using Qiagen RNeasy
(QIAGEN, Toronto). First-strand cDNA was synthesised from 2mg
of total RNA using High Capacity cDNA Reverse Transcription
Kit (Applied Biosystems). Semi quantitative RT-PCR was
performed using primers for VEGF-A, -C, and -D, COX-2,
VEGF-R2, -R3 and GAPDH [7,9]. Quantitative (q) RT-PCR was
Figure 12. Metastatic spread of tumor cells to the draining lymph nodes is abrogated by a9 integrin and VEGF-D knock down in
468LN cells: (A) Metastasis to lymph nodes were validated by the visual localisation of many cancer cells in 468LN tumor draining nodes identified
by the GFP-marker and their absence in lymph nodes draining a9 integrin and VEGF-D knock down tumor implants. Nuclei were stained blue by
DAPI. (B, C) Above conclusions were further validated by measuring the human mitochondrial-specific marker MTCO2 at the mRNA level with qRT-
PCR (B) and protein level with western blot (C) was high in lymph nodes draining 468LN tumors. This process was nearly completely abrogated in
both Da9/468LN and DVEGF-D/468LN tumor implants. Data were derived from 16 lymph nodes. Four lymph nodes draining into an individual tumor
in a single mouse were pooled to extract RNA and proteins, showing the data in four mice; Matrigel was retrieved from four implants. Data represents
mean (n=4) 6 S.E, *p,0.05, *p,0.001.
doi:10.1371/journal.pone.0035094.g012
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mouse (LYVE-1 and b-actin) genes with TaqMan Gene
Expression Assays (Applied Biosystems).
Protein detection and measurement
To measure protein levels with western blot, cells, tumor and
lymph node specimens were lysed with RIPA buffer containing
Halt
TM Protease Inhibitor Cocktail (PIERCE, Rockford IL), and
15–20 mg protein was run on 10–12% SDS-PAGE gel. Human
VEGF-A, -C, -D, -R2, -R3, COX-2, a9, MTCO2 and GAPDH
proteins were detected by using monoclonal anti human VEGF-A
(sc-507), VEGF-C (sc-1881), VEGF-D (sc-13085), COX-2 (sc-
1747) from Santa Cruz Biotechnology, CA,VEGF-R2 (55B11) and
VEGF-R3 (C28G5) from Cell Signaling Technology (Danvers,
MA), integrin a9 (MAB4574) (R&D Systems, MN), GAPDH
(MAB374) from Millipore (Billerica, MA) antibodies and MTCO2
(ab3298) from Abcam, US. Mouse b-actin and LYVE-1 proteins
were detected by using anti mouse b-actin (sc-47778) from Santa
Cruz and LYVE-1 (cat. no.11–034) from Angiobio, US. Erk1/2
and phospho Erk1/2 proteins were measured using monoclonal
anti human antibodies (9102 and 9101S) from Cell Signaling.
IRDye 800 conjugated anti-rabbit IgG (VEGF-A, -D, -R2, -R3,
Erk1/2, pErk1/2, LYVE-1), anti-goat IgG (VEGF-C, COX-2)
(Rockland Immunochemicals, Gilbertsville, PA) and Alexa 680
conjugated anti-mouse IgG (Molecular Probes/Invitrogen) were
used as secondary antibodies. Immunoblots were quantified with
Odyssey Infrared Imaging System (LI-COR Biosciences). Secreted
VEGF-C and -D proteins were measured with QuantikineH
Human VEGF-C (DVEC00) and -D (DVED00) Immunoassay
(R&D Systems, MN).
Migration, invasion and proliferation assay
Cellular migration and invasion (at 24 h and 48 h respectively)
were measured as reported earlier [9,57] with minor modifica-
tions. Near confluent cells were serum starved overnight. Then,
4610
4 cells/ml cells in an antibiotic-free medium and respective
treatments were placed in the upper insert and allowed to migrate
or invade; the bottom well was filled with the same solution used to
re-suspend the cells (for native migration) or solutions inclusive of
treatments (for experimental migration). The presence of 2% FBS
to the basal medium served as positive controls for stimulation.
The assembled cell culture insert chambers were then incubated at
37uC, 5% CO2 for 24 h for migration and 48 h for invasion. On
completion of the incubation, the upper surfaces of the
membranes were wiped gently with cotton swabs to remove
non-migratory cells. The use of time points for scoring the number
of migrating or invading cells at the bottom-side of membranes
were based on pilot experiments, in which both events reached
their peaks under native or serum stimulated conditions. The
membranes were then fixed and stained, and the absolute number
of migrating cells was scored visually using light microscope (40X
objectives). Effects of exogenous recombinant VEGF-D (rVEGF-
D) (2.5 ng/ml) (622-VD-005, R&D Systems) on both HMVEC-
dLy and cancer cells, monoclonal anti human a9/b1 blocking
antibody (sc-59969) (Santa Cruz, CA) on cancer cells, and Erk
inhibitor (U0126 from Cell Signaling) on HMVEC-dLy cells were
tested at the migration and invasion levels. In some experiments
measuring migration of HMVEC-dLy cells, cell free supernatant
(or conditioned medium) of 468GFP or 468LN cells were included
in the bottom chamber as a source of stimulus. Each treatment
was performed in triplicate or quadruplicate. Breast cancer cell
proliferation was measured using Cell Proliferation ELISA kit
(Roche Applied Science, IN). Briefly, cells were grown in 96-well
Figure 13. Ability to induce intra-tumoral lymphangiogenesis was abrogated by both VEGF-D and a9 integrin knock down in
468LN cells: (A, B) Intra-tumoral lymphangiogenesis was measured indirectly from the expression of murine lymphatic endothelial marker LYVE-1 in
tumors at the mRNA level with qRT-PCR (A) and protein level with western blot (B). Murine LYVE-1 expression was very high in 468LN tumors and this
expression was nearly completely abolished in both Da9/468LN and DVEGF-D/468LN tumor implants. Data were derived from 16 tumors. Four
tumors in a single mouse were pooled to extract RNA and proteins, showing the data in four mice; Matrigel was retrieved from four implants. Data
represents mean (n=4) 6 S.E, *p,0.05, *p,0.001.
doi:10.1371/journal.pone.0035094.g013
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4 cells/well) for 24 h in complete
medium and incubated with BrdU for another 4 h. After removal
of BrdU containing medium, cells were fixed and anti-BrdU-POD
antibody was added, which recognises the BrdU incorporated into
the newly synthesized cellular DNA. The immune complexes were
detected by the subsequent substrate reaction. The reaction
product was quantified by measuring the absorbance using a
scanning multi-well spectrophotometer (Tecan, Infinite M200).
In vitro lymphangiogenesis (tube formation) assay
Semi confluent HMVEC-dLy cells were grown on 12-well tissue
culture plates (2610
5 cells/per well) evenly coated with 0.1 ml/
well growth factor-reduced Matrigel (BD Biosciences, San Jose,
CA), diluted with serum free medium in 1:1 ratio. The time course
of tube formation in serum free medium (SFM) under control or
experimental conditions was recorded with a fluorescence
microscope (Leica DFC340FX). Vascular-like channels were
quantified by counting the total number of complete tubes and
the number of branching points in the same field at different (x5
and x10) objectives using ImageJ software. When cells connected
to each other to complete a capillary like structure was called a
tube, whereas, each point connecting rows of cells was called a
branching point [58]. Five randomly selected fields of view with
x10 objective were photographed in each well. The average of five
fields was taken as the value for each sample. Finally data from
triplicate or quadruplicate experiments were expressed as a
percentage of the respective controls.
Mice
Six weeks old athymic nude female mice (Hsd: Athymic Nude-
Foxn1
nu/Foxn1
+, Harlan, IN), were allowed to acclimatize for 2–
3 weeks, maintained on standard mouse chow and tap water
(unless otherwise indicated) on a 12 h light/dark cycle, and treated
in accordance with the guidelines set by the Canadian Council on
Animal Care.
Tumor transplantation and measurements of tumor
progression
Tumor growth, tumor-associated angiogenesis, lymphangiogen-
esis and lymphatic metastasis were measured with an in vivo assay
devised in our laboratory [39] in which tumor cells suspended in
growth factor reduced Matrigel were implanted S.C., allowing
ingrowths of capillaries and lymphatics from pre-existing vascu-
lature. Originally devised for measuring the kinetics of tumor-
associated angiogenesis [39], our pilot studies revealed that this in
vivo assay was also exquisitely suited for measuring tumor-
associated lymphangiogenesis. Mice were randomized into control
and experimental groups and received subcutaneous implants of
20610
4 either 468LN or DVEGF-D/468LN or Da9/468LN cells
suspended in growth factor reduced Matrigel (3.5 mg Matrigel in
0.5 ml aMEM) in both inguinal and axillary mammary regions
(each animal four points). Some animals received implants of
Matrigel alone, to serve as negative controls for angiogenesis or
lymphangiogenesis and lymphatic metastasis. The tumor volumes
measured externally with calliper at 2 days intervals (computed as
0.56a
2 b, from the minimum (a) and maximum (b) diameters) as
Figure 14. Intra-tumoral lymphangiogenesis (LYVE-1 immunostatining-red) as well as angiogenesis (CD31 immunostaining-red)
were abrogated by both a9 integrin and VEGF-D knock down in 468LN cells: (A) Direct measurements of lymphangiogenesis and
angiogenesis respectively identified with immunofluorescent labelling for murine LYVE-1 and CD31 markers in serial frozen sections of tumors
revealed significantly higher labelling for both markers in 468LN tumors compared to Da9/468LN and DVEGF-D/468LN tumors. Nuclei were stained
with DAPI (blue). (B) Fluorescence was quantified as corresponding ‘‘hot spot’’ scores. (n=16, using the mean of 3 hot spots from each of the 16
tumors per group; Matrigel implants, n=4) 6 S.E, **p,0.001.
doi:10.1371/journal.pone.0035094.g014
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Mice were sacrificed by exposure to halothane followed by cervical
dislocation, at day 20 (n=4 for each cell line). Upon retrieval of
the Matrigel implants (4 per mouse) at day 20, gross morphology
of tumor and tumor draining lymph nodes were photographed.
Tumors and tumor-draining lymph nodes were then sliced in three
pieces, one for frozen section for further histological or immuno-
histological analysis, other parts for RNA and protein extraction
respectively. Implants of Matrigel alone at four points in one
mouse remained unchanged in size, serving as negative control.
Evans Blue visualization of lymphatic vessels in vivo
After the tumors had grown to between 0.5 and 1 cm in
diameter, the mice were anesthetised with isoflurane (Pharmaceu-
tical Partners Of Canada Inc., ON) and the tumors were exposed.
To identify the lymphatics in nude mice, 2 ml of 4% Evan’s blue
dye (Sigma-Aldrich, CA) in PBS were injected 2 cm apart from the
tumor at a single point, allowing a visual tracing of lymphatics into
both 468LN and DVEGF-D/468LN tumors. Images were
acquired with a digital camera (Nikon, D-90) at 5 minutes and
then consecutive pictures were taken with dissection microscope
(Nikon SMZ1500) after 10–25 minutes to identify lymphatic
vessels impinging on the tumor.
Measurements of angiogenesis and lymphangiogenesis
Eight micrometer (mm) thick frozen sections of Matrigel
implants were fixed in methanol for 3 minutes and then in
acetone for 3 minutes, both at 4uC. All of the subsequent steps
were performed at room temperature. Sections were air-dried for
1h, rehydrated for 10 minutes in PBS, followed by treatment with
2% BSA in PBS for 20 minutes to block non-specific antibody
binding. Sections were then incubated for 1 h with rabbit anti-
mouse LYVE-1 (Upstate biotechnologies, Lake Placid, NY; 1:200)
and rat anti-mouse CD31 (Caltag Laboratories, Advanced medical
sciences, Bangkok, Thailand, 1:1000) antibodies, followed by
normal mouse serum (1%) for 10 minutes to block non-specific
cross-reactivity of secondary antibodies with mouse proteins.
Nuclei were stained with DAPI (4, 6-diamidine-2-phenylindole
hydrochloride, 1:10,000) from Invitrogen. Sections were then
incubated for 30 minutes with goat anti-rabbit Alexa Fluor 488
and donkey anti-rat Alexa Fluor 594 secondary antibodies
(Molecular Probes, Burlington, ON, Canada; 1:1000), washed
with PBS, drained, and mounted with Vectashield solution (Vector
Laboratories, Burlington, ON). The sections from all tumors were
first scanned at low magnification (2506) under a BX51
microscope (Olympus) to identify the most vascular areas of the
tumor. Microvessel density (MVD) representing blood vessels and
lymphatic vessel density (LVD) were assessed in serial immuno-
stained sections of frozen tissues as reported [39,40], with the
following modification. Three hotspots per tumor (4 tumor per
mouse64mice63 spots or 48/group) were examined at 406mag-
nification [40], and scored after setting the threshold for
background, using the Image-J software (NIH, USA). The mean
values for MVD and LVD were computed as the staining indices
for CD31 (red) and LYVE-1 (red), respectively.
Indirect quantification of lymphangiogenesis
Total RNA and protein were extracted from tumors. Presence
of murine lymphatic endothelial cells in tumors resulting from
transplantation of human cancer cells were quantified with
Taqman Gene expression assay using mouse specific probe for
the lymphatic endothelial cell marker LYVE-1
(Mm00475056_m1, cat no. 4331182, Applied Biosystems), and
Figure 15. Schematic representation of the cross talk between tumor cells and lymphatic endothelial cells: (A) In autocrine regulation,
VEGF-D produced by 468LN breast cancer cell line binds to a9b1 integrin cell surface receptor to induce the migration and invasion of cancer cell via
Erk signaling. (B) In paracrine regulation, VEGF-D secreted by 468LN cells binds to VEGF-R3 on lymphatic endothelial cell (LEC) surface and induces
migration and tube formation by the LEC via Erk signaling. (C) Binding of VEGF-D to a9b1 integrin located on the cancer cell membrane still leaves its
binding site for VEGF-R3 located on the LEC membrane unoccupied. This leads to dual signaling by this ligand for both tumor and endothelial cells in
a highly localised manner, defined as juxtacrine regulation.
doi:10.1371/journal.pone.0035094.g015
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(cat no. 11–034, Angiobio, US).
Quantification of lymphatic metastasis
Total RNA and protein were extracted from tumor draining
lymph nodes. Presence of human cancer cells in mouse lymph
nodes was quantified with Taqman Gene expression assay with
human mitochondrial gene (MT-CO2) specific probe
(Hs02596865_g1, Gene ID 4513, Applied Biosystems), and
monoclonal antibody to MTCO2 (1–2 mg/ml; ab3298; Abcam,
US) that reacts specifically with a 60 kDa non-glycosylated protein
component of human mitochondria. In addition using frozen
sections of draining lymph nodes, green 468LN cells (resulting
from the GFP marker) were identified with fluorescence
microscopy.
Statistics
All statistical analyses were performed using GraphPad
Software (QuickCalcs). Data were analysed by two way ANOVA
and Student’s T-test considering P,0.05 as an indicator of
significant difference between means.
Supporting Information
Figure S1 Compared to 468GFP cells, 468LN cells were
significantly more proliferative. (B) Representative images of
migratory 468GFP and 468LN cells in SFM. (C) 468LN cells
expressed a significantly higher level of VEGF-D mRNA
measured with qRT-PCR. (D) Representative images of migratory
468GFP and 468LN cells in the presence of rVEGF-D. Images
were obtained under 40X objective after 24 h incubation.
(TIF)
Figure S2 Representative images of migratory 468LN cells in
SFM and before and after VEGF-D knock down. Images were
obtained under 40X objective after 24 h incubation.
(TIF)
Figure S3 Migration pictures of pictures of 468LN cells showing
results after a9 integrin knock down in SFM, in the presence of
rVEGF-D or FBS. Images were captured with 40X objective after
24 h incubation.
(TIF)
Figure S4 Representative migration of pictures of 468LN cells in
SFM and in the presence of RAW cell conditioned medium (CM)
before and after a9 integrin knock down. Images were captured
with 40X objective.
(TIF)
Figure S5 Migration pictures of HMVEC-dLy cells in presence
of 468GFP, 468LN cells, VEGF-D knocked down 468LN cells and
after addition of exogenous rVEGF-D. Images were captured with
20X objective.
(TIF)
Figure S6 Migration pictures of rVEGF-D stimulated HMVEC-
dLy cells and inhibition of migration of the same cells in response
to Erk inhibitor U0126 at different concentrations. Inhibition
could not be retrieved with exogenous rVEGF-D. Images were
captured with 40X objective.
(TIF)
Figure S7 Stable knock down of a9 integrin and VEGF-D
with shRNA plasmid: Stable knock down of both a9 integrin
and VEGF-D in 468LN cells was confirmed at protein level.
Western blots showing 60–70% knock down of a9 integrin and
VEGF-D compared to shRNA control knock down. The stable
cell lines were named as Da9/468LN and DVEGF-D/468LN for
a9 integrin and VEGF-D knock down respectively.
(TIF)
Figure S8 Estimation of 468LN cells metastasizing to
the tumor draining lymph nodes by real time PCR:
468LN cells were plated overnight for complete attachment. And
then one million cells harvested to extract RNA. Then cDNA was
synthesised with 2 mg of total RNA. Next, serial dilutions (1:5) of
cDNAs were prepared using the nuclease free water. Then real-
time RT-PCR was performed with all diluted 468LN cDNAs.
This was done concurrently with cDNAs derived with RNA
extracted from lymph nodes. The Ct value obtained with the
lymph node was then converted to the number of tumor cells from
the standard plot.
(TIF)
Figure S9 Screening of different breast cancer cell lines for
VEGF-D (A) and for a9 integrin (B) at mRNA levels with qRT-
PCR and (C) protein levels with western blot. Expression of
mRNA levels in different cell lines were quantitated relative to the
expression in MCF-7 cells and presented in a log scale. Data are
expressed as mean 6 SE for replicate values, ** p,0.001.
(TIF)
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